Cipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company aims to improve top line growth in Europe and expand margins in South Africa. It will focus on commercial execution, resolving USFDA observations, and growing private and select tender business. Derisking top launches and resolving regulatory issues at manufacturing plants are top priorities.
